Filing Details
- Accession Number:
- 0001104659-19-032914
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-30 21:25:55
- Reporting Period:
- 2019-05-28
- Accepted Time:
- 2019-05-30 21:25:55
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1761612 | Bicycle Therapeutics Plc | BCYC | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1777210 | Deborah Harland | C/O S.r. One, Limited 161 Washington Street, Suite 500 Conshohocken PA 19428 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Acquisiton | 2019-05-28 | 893,195 | $0.00 | 893,195 | No | 4 | C | Indirect | See Footnote |
Ordinary Shares | Acquisiton | 2019-05-28 | 636,366 | $0.00 | 1,529,561 | No | 4 | C | Indirect | See Footnote |
Ordinary Shares | Acquisiton | 2019-05-28 | 385,714 | $14.00 | 1,915,275 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnote |
No | 4 | C | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Series A Preferred Shares | Disposition | 2019-05-28 | 893,195 | $0.00 | 893,195 | $0.00 |
Ordinary Shares | Series B1 Preferred Shares | Disposition | 2019-05-28 | 636,366 | $0.00 | 636,366 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein. Deborah Harland holds the title of Vice President at S.R. One, Limited and is an employee of GlaxoSmithKline Services Unlimited, a wholly-owned subsidiary of GlaxoSmithKline plc. Ms. Harland disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of her pecuniary interest therein.